Prospective Grant of an Exclusive Patent License: Use and Development of RAB13 and NET1 Targeting Antisense Oligonucleotides in the Treatment of Cancer, 74648 [2022-26430]

Download as PDF 74648 Federal Register / Vol. 87, No. 233 / Tuesday, December 6, 2022 / Notices Dated: November 30, 2022. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.866, Aging Research, National Institutes of Health, HHS) [FR Doc. 2022–26431 Filed 12–5–22; 8:45 am] Dated: December 1, 2022. Miguelina Perez, Program Analyst, Office of Federal Advisory Committee Policy. BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES [FR Doc. 2022–26467 Filed 12–5–22; 8:45 am] BILLING CODE 4140–01–P National Institutes of Health DEPARTMENT OF HEALTH AND HUMAN SERVICES Prospective Grant of an Exclusive Patent License: Use and Development of RAB13 and NET1 Targeting Antisense Oligonucleotides in the Treatment of Cancer National Institutes of Health AGENCY: National Institute of General Medical Sciences; Notice of Meeting ACTION: lotter on DSK11XQN23PROD with NOTICES1 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel; Review of PRAT applications. Date: March 7, 2023. Time: 10:00 a.m. to 6:00 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, National Institute of General Medical Sciences, Natcher Building, 45 Center Drive, Bethesda, MD 20892 (Virtual Meeting). Contact Person: Lee Warren Slice, Ph.D., Scientific Review Officer, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, 45 Center Drive, Room 3AN12, Bethesda, MD 20892, 301–435–0807, slicelw@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives; 93.859, Biomedical Research and Research Training, National Institutes of Health, HHS) VerDate Sep<11>2014 17:51 Dec 05, 2022 Jkt 259001 National Institutes of Health, HHS. Notice. The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the U.S. Patents and Patent Applications listed in the Supplementary Information section of this notice to Drug Development and Filing Consulting, LLC located in Maryland, USA. DATES: Only written comments and/or applications for a license which are received by the National Cancer Institute’s Technology Transfer Center on or before December 21, 2022 will be considered. ADDRESSES: Requests for copies of the patent application, inquiries, and comments relating to the contemplated an Exclusive Patent License should be directed to: Suna Gulay French, Technology Transfer Manager, Telephone: (240)-276–7424; Email: suna.gulay@nih.gov. SUPPLEMENTARY INFORMATION: SUMMARY: Intellectual Property 1. United States Provisional Patent Application No. 62/966,204, filed January 27, 2020 and entitled ‘‘RAB13 and NET1 Antisense Oligonucleotides to Treat Metastatic Cancer’’ [HHS Ref. No. E–041–2020–0–US–01]; 2. PCT Patent Application No. PCT/ US2021/015053, filed January 26, 2021 and entitled ‘‘RAB13 and NET1 Antisense Oligonucleotides to Treat Metastatic Cancer’’ [HHS Ref. No. E– 041–2020–0–PCT–02]; and 3. United States Patent Application No. 17/792,507, filed July 13, 2022 and entitled ‘‘Antisense Oligos that Block Cancer Cell Migration and Invasion’’ [HHS Ref. No. E–041–2020–0–US–03]. PO 00000 Frm 00054 Fmt 4703 Sfmt 9990 The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America. The prospective exclusive license territory may be the United States only and the field of use may be limited to: ‘‘Use and development of RAB13 and NET1 targeting antisense oligonucleotides in treatment of breast cancer, ovarian cancer, cervical cancer and head and neck cancer in humans.’’ This technology discloses RAB13 and NET1 targeting antisense oligonucleotides (ASOs) for use in targeted cancer therapy. These ASOs bind to the 3′-untranslated regions of RAB13 and NET1 mRNAs and prevent the localization of these mRNAs to cellular protrusions involved in motility. These ASOs reduce cell motility and migration in vitro. Due to this reduction in cell motility and migration, these ASOs are expected to have uses in the treatment of metastatic cancers. This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404. In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available. License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552. Dated: November 30, 2022. Richard U. Rodriguez, Associate Director, Technology Transfer Center, National Cancer Institute. [FR Doc. 2022–26430 Filed 12–5–22; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\06DEN1.SGM 06DEN1

Agencies

[Federal Register Volume 87, Number 233 (Tuesday, December 6, 2022)]
[Notices]
[Page 74648]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-26430]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of an Exclusive Patent License: Use and 
Development of RAB13 and NET1 Targeting Antisense Oligonucleotides in 
the Treatment of Cancer

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Cancer Institute, an institute of the National 
Institutes of Health, Department of Health and Human Services, is 
contemplating the grant of an Exclusive Patent License to practice the 
inventions embodied in the U.S. Patents and Patent Applications listed 
in the Supplementary Information section of this notice to Drug 
Development and Filing Consulting, LLC located in Maryland, USA.

DATES: Only written comments and/or applications for a license which 
are received by the National Cancer Institute's Technology Transfer 
Center on or before December 21, 2022 will be considered.

ADDRESSES: Requests for copies of the patent application, inquiries, 
and comments relating to the contemplated an Exclusive Patent License 
should be directed to: Suna Gulay French, Technology Transfer Manager, 
Telephone: (240)-276-7424; Email: [email protected].

SUPPLEMENTARY INFORMATION: 

Intellectual Property

    1. United States Provisional Patent Application No. 62/966,204, 
filed January 27, 2020 and entitled ``RAB13 and NET1 Antisense 
Oligonucleotides to Treat Metastatic Cancer'' [HHS Ref. No. E-041-2020-
0-US-01];
    2. PCT Patent Application No. PCT/US2021/015053, filed January 26, 
2021 and entitled ``RAB13 and NET1 Antisense Oligonucleotides to Treat 
Metastatic Cancer'' [HHS Ref. No. E-041-2020-0-PCT-02]; and
    3. United States Patent Application No. 17/792,507, filed July 13, 
2022 and entitled ``Antisense Oligos that Block Cancer Cell Migration 
and Invasion'' [HHS Ref. No. E-041-2020-0-US-03].
    The patent rights in these inventions have been assigned and/or 
exclusively licensed to the government of the United States of America.
    The prospective exclusive license territory may be the United 
States only and the field of use may be limited to: ``Use and 
development of RAB13 and NET1 targeting antisense oligonucleotides in 
treatment of breast cancer, ovarian cancer, cervical cancer and head 
and neck cancer in humans.''
    This technology discloses RAB13 and NET1 targeting antisense 
oligonucleotides (ASOs) for use in targeted cancer therapy. These ASOs 
bind to the 3'-untranslated regions of RAB13 and NET1 mRNAs and prevent 
the localization of these mRNAs to cellular protrusions involved in 
motility. These ASOs reduce cell motility and migration in vitro. Due 
to this reduction in cell motility and migration, these ASOs are 
expected to have uses in the treatment of metastatic cancers.
    This notice is made in accordance with 35 U.S.C. 209 and 37 CFR 
part 404. The prospective exclusive license will be royalty bearing, 
and the prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the National 
Cancer Institute receives written evidence and argument that 
establishes that the grant of the license would not be consistent with 
the requirements of 35 U.S.C. 209 and 37 CFR part 404.
    In response to this Notice, the public may file comments or 
objections. Comments and objections, other than those in the form of a 
license application, will not be treated confidentially, and may be 
made publicly available.
    License applications submitted in response to this Notice will be 
presumed to contain business confidential information and any release 
of information in these license applications will be made only as 
required and upon a request under the Freedom of Information Act, 5 
U.S.C. 552.

    Dated: November 30, 2022.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2022-26430 Filed 12-5-22; 8:45 am]
BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.